Indaptus Therapeutics, Inc. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net
Indaptus Therapeutics, Inc. (INDP) had Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net of $8.73 million as of 2021-08-03, per its 10-K filed 2022-03-21.
Discontinued › Notes › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less)
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet · last filed 2022-03-21
- 2021-08-03: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net $8.73M.
| Period end | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net |
|---|---|
| 2021-08-03 | $8.73M 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |